Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123484 | 0.90 | MEN1 (0.49) | KMT2AMEN1GLP1RTSHRALDH1A1 | |
| SCHEMBL25704881 | 0.88 | MEN1 (0.50) | KMT2AMEN1GLP1RTSHRALDH1A1 | |
| SCHEMBL23945215 | 0.87 | MEN1 (0.49) | KMT2AMEN1GLP1RTSHRLMNA | |
| SCHEMBL21105932 | 0.84 | KMT2A (0.59) | KMT2AMEN1GLP1RTSHRSMN1; SMN2 | |
| SCHEMBL21105478 | 0.84 | KMT2A (0.59) | KMT2AMEN1GLP1RTSHRSMN1; SMN2 | |
| SCHEMBL22837635 | 0.84 | KMT2A (0.59) | KMT2AMEN1GLP1RTSHRSMN1; SMN2 | |
| SCHEMBL25546667 | 0.84 | KMT2A (0.59) | KMT2AMEN1GLP1RTSHRSMN1; SMN2 | |
| SCHEMBL25769651 | 0.83 | MEN1 (0.39) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25971783 | 0.82 | MEN1 (0.32) | KMT2AMEN1TSHRTLR2 | |
| SCHEMBL19050851 | 0.81 | KMT2A (0.63) | KMT2AMEN1GLP1RTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885GLP1R 2955/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.